The biomarkers have been used routinely in many areas in medicine for accurate diagnosis, management, prognosis and risk stratification. Cardiac biomarkers are essential for the definition of acute myocardial infarction and heart failure and are also a powerful tool for triaging. The introduction of a high-sensitivity troponin assay has been useful in patients with non-STEMI,
which allows diagnosis by a single measurement and a serial measurement. “High-sensitivity” refers to analytical, which detect troponin precisely in a very low concentration.
BNP and NT-proBNP are widely used to help in distinguishing patients with cardiac dyspnea from with non-cardiac disease. The incorporation of BNP and NT-proBNP into routine clinical care is the first step into the realm of biomarker-supported evaluation and management of patients with heart failure.
In this session, the current application of troponin and BNP/NT-proBNP will be reviewed.
Beckman Coulter is committed to advancing healthcare for every person by applying the power of science, technology and the passion and creativity of our teams to enhance the diagnostic laboratory’s role in improving healthcare outcomes. Our diagnostic systems are used in complex biomedical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. Beckman Coulter offers a unique combination of people, processes and solutions designed to elevate the performance of clinical laboratories and healthcare networks. We do this by accelerating care with a menu that matters, bringing the benefit of automation to all, delivering greater insights through clinical informatics and unlocking hidden value through performance partnership. An operating company of Danaher Corporation (NYSE: DHR) since 2011, Beckman Coulter is headquartered in Brea, California, and has more than 11,000 global associates working diligently to make the world a healthier place.
Monocyte Distribution Width (MDW), proprietary to Beckman Coulter analyzers, is the regulatory-cleared hematological biomarker that helps to establish severity of infection and risk of sepsis in adult patients in the emergency department. MDW is a measure of increased morphological variability of monocytes in response to bacterial, viral or fungal infections. MDW is reported automatically as part of a routine CBC with Differential test on the DxH 900 and DxH 690T hematology analyzers using the Early Sepsis Indicator (ESId) application*, which enables automatic reporting with no workflow changes or need to order an additional test. MDW has been studied for the past decade with more than 16 peer-review publications and over 21,000+ patients1, confirming the robustness and reproducibility of MDW performance in different patient populations. MDW has cleared for FDA and acquired CE mark and mFDS and Early Sepsis Indicator (ESId) application is required to see Monocyte Distribution Width(MDW) on DxH 900.
At a time when up to 75% of lab errors occur pre-analytically, analytical all laboratories could benefit from comprehensive workflow automation. That’s where DxA 5000 Fit, an automation system that offers a fundamentally improved approach to laboratory workflow by making intelligent automation accessible to labs of virtually any size. It is good opportunity to implement Automation solution with optimized performance into the space. The DxA 5000 Fit automation solution processes blood and urine sample tubes for core disciplines such as chemistry and immunoassay. It can perform sample login, sample tube characterization, centrifugation, decapping, presentation of samples to connected analytical instruments, placed in ambient storage and sorting to output racks. Additionally, DxA 5000 Fit can automatically retrieve and rerun or reflex sample tubes through REMISOL Advance data management software. The DxA 5000 Fit drives speed and accuracy, all while maintaining a small footprint. It eliminates up to 80% of the manual steps associated with processing a patient sample, allowing you to keep your focus on what matters most ; patient care.
Successful management of cardiovascular diseases means mitigating adverse events by making the right decisions. Clinicians want to diagnose and initiate appropriate treatment quickly to improve patient outcomes. Cardiovascular diseases account for an estimated 31% of all deaths worldwide and are the number one cause of death globally, killing ~17.9 million people each year. Four out of five cardiovascular diseases deaths are due to heart attacks and strokes, and one third of these deaths occur prematurely in people under 70 years of age1. The annual global cost of cardiovascular diseases is estimated to rise to $1,044 billion USD by 20302 . Diagnostic Support for Assessing Patients at Risk for or Experiencing Cardiovascular Diseases Clinical laboratories can improve care for patients experiencing, or at risk for, cardiovascular disease. The speed and accuracy of the information your laboratory delivers are critical to improving patient outcomes and reducing the cost of care. Beckman Coulter's comprehensive cardiac diagnostics menu provides the tests your laboratory needs to support informed clinical decision making. • Access hsTnI • CK-MB (Creatine Kinase Myocardial Band) • Digoxin • Myoglobin • Access BNP Natriuretic peptides reflect cardiac status and effects of therapy Natriuretic peptides are proteins secreted by the heart in response to volume or pressure overload. They are important biomarkers in the diagnosis of heart failure.3 Achieve greater clinical insights to improve the management of heart failure patients across the disease spectrum from diagnosis to risk stratification and ongoing assessments of severity with Beckman Coulter’s Access BNP. Reference 1.Cardiovascular diseases. (n.d.). from Who.int website: https://www.who.int/health-topics/cardiovascular-diseases [Accessed March 8, 2023] 2.Institute for Health Metrics and Evaluation (IHME). The Global Burden of Diseases, Injuries and Risk Factors Study 2010 (GBD 2010). Generating Evidence, Guiding Policy Report 3.Borke, J. Natriuretic Peptides in Congestive Heart Failure. March 9, 2021. Medscape. https://emedicine.medscape.com/article/761722-overview